1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Synthesis and Glycosidase Inhibition of Broussonetine M and Its Analogues

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cross-metathesis (CM) and Keck asymmetric allylation, which allows access to defined stereochemistry of a remote side chain hydroxyl group, are the key steps in a versatile synthesis of broussonetine M ( 3) from the d-arabinose-derived cyclic nitrone 14. By a similar strategy, ent-broussonetine M ( ent-3 ) and six other stereoisomers have been synthesized, respectively, starting from l- arabino-nitrone ( ent-14 ), l- lyxo-nitrone ( ent-3- epi-14 ), and l- xylo-nitrone ( 2- epi-14 ) in five steps, in 26%–31% overall yield. The natural product broussonetine M ( 3) and 10’- epi-3 were potent inhibitors of β-glucosidase (IC 50 = 6.3 μM and 0.8 μM, respectively) and β-galactosidase (IC 50 = 2.3 μM and 0.2 μM, respectively); while their enantiomers, ent-3 and ent-10’- epi-3 , were selective and potent inhibitors of rice α-glucosidase (IC 50 = 1.2 μM and 1.3 μM, respectively) and rat intestinal maltase (IC 50 = 0.29 μM and 18 μM, respectively). Both the configuration of the polyhydroxylated pyrrolidine ring and C-10’ hydroxyl on the alkyl side chain affect the specificity and potency of glycosidase inhibition.

          Related collections

          Most cited references62

          • Record: found
          • Abstract: found
          • Article: not found

          A general model for selectivity in olefin cross metathesis.

          In recent years, olefin cross metathesis (CM) has emerged as a powerful and convenient synthetic technique in organic chemistry; however, as a general synthetic method, CM has been limited by the lack of predictability in product selectivity and stereoselectivity. Investigations into olefin cross metathesis with several classes of olefins, including substituted and functionalized styrenes, secondary allylic alcohols, tertiary allylic alcohols, and olefins with alpha-quaternary centers, have led to a general model useful for the prediction of product selectivity and stereoselectivity in cross metathesis. As a general ranking of olefin reactivity in CM, olefins can be categorized by their relative abilities to undergo homodimerization via cross metathesis and the susceptibility of their homodimers toward secondary metathesis reactions. When an olefin of high reactivity is reacted with an olefin of lower reactivity (sterically bulky, electron-deficient, etc.), selective cross metathesis can be achieved using feedstock stoichiometries as low as 1:1. By employing a metathesis catalyst with the appropriate activity, selective cross metathesis reactions can be achieved with a wide variety of electron-rich, electron-deficient, and sterically bulky olefins. Application of this model has allowed for the prediction and development of selective cross metathesis reactions, culminating in unprecedented three-component intermolecular cross metathesis reactions.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Iminosugars as therapeutic agents: recent advances and promising trends.

              For the purpose of this article, iminosugars are polyhydroxylated secondary and tertiary amines in which the molecules resemble monosaccharide sugars in which the ring oxygen is replaced by the nitrogen. The bicyclic structures may biologically resemble disaccharides. Very few iminosugars have been available up to now for evaluation of their pharmaceutical applications. The early compounds were discovered and selected for study due to glycosidase inhibition, which is now known to not be necessary for pharmacological activity and may cause off-target effects. Glyset® and Zavesca®, derived from the glucosidase-inhibiting natural product 1-deoxynojirimycin, are the first two examples of iminosugar drugs. Since the discovery of this first generation, many new natural products have been identified with a wide range of biological activities but few are widely available. Among the biological properties of these compounds are good oral bioavailability and very specific immune modulatory and chaperoning activity. Although the natural products from plants and microorganisms can have good specificity, modifications of the template natural products have been very successful recently in producing bioactive compounds with good profiles. The field of iminosugars continues to open up exciting new opportunities for therapeutic agent discovery and offers many new tools for precisely modifying carbohydrate structures and modulating glycosidase activity in vivo. Current efforts are directed towards a greater range of structures and a wider range of biochemical targets.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Molecules
                Molecules
                molecules
                Molecules
                MDPI
                1420-3049
                15 October 2019
                October 2019
                : 24
                : 20
                : 3712
                Affiliations
                [1 ]Beijing National Laboratory for Molecular Science (BNLMS), CAS Key Laboratory of Molecular Recognition and Function, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; lsqkwu@ 123456iccas.ac.cn (Q.-K.W.); tamarali@ 123456iccas.ac.cn (Y.-X.L.); jiayuemei@ 123456iccas.ac.cn (Y.-M.J.)
                [2 ]University of Chinese Academy of Sciences, Beijing 100049, China
                [3 ]Department of Hospital Pharmacy, University of Toyama, 2630 Sugitani, Toyama 930–0194, Japan; kimagure1242@ 123456yahoo.co.jp
                [4 ]Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road, Oxford OX13TA, UK
                [5 ]National Engineering Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, China
                Author notes
                [* ]Correspondence: kato@ 123456med.u-toyama.ac.jp (A.K.); yucy@ 123456iccas.ac.cn (C.-Y.Y.); Tel.: +86-010-626-12893 (C.-Y.Y.)
                Author information
                https://orcid.org/0000-0001-8022-196X
                https://orcid.org/0000-0002-8389-0349
                Article
                molecules-24-03712
                10.3390/molecules24203712
                6832352
                31619020
                12300cf7-0447-4664-b4be-c4015bf2cdd4
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 17 September 2019
                : 14 October 2019
                Categories
                Article

                broussonetine m,analogue,synthesis,glycosidase inhibition,structure-activity relationship

                Comments

                Comment on this article